CIN No.: L24230TG1995PLC020093

Regd. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA. Admin Office: 3-11-451, L B Nagar, Hyderabad - 500074

E-mail: concorddrugsltd@gmail.com

Ph.No: +91 9052779505

Website: www.concorddrugs.in

To,

Date: 28.04.2023

BSE Limited P.J. Towers, Dalal Street Mumbai-400001

Dear Sir/ Madam,

Sub: Disclosure under Regulation 40(9) of SEBI (Listing Obligation and Disclosure

Requirements) Regulations, 2015

Ref: Scrip Code: 538965

With reference to the subject cited, please find enclosed the disclosure u/r 40(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the financial year ended 31.03.2023.

This is for the information and records of the Exchange, please.

Thanking you.


Yours sincerely, For Concord Drugs Limited

5 Ns ruy S. Nagi Reddy

Chairman & Whole time Director

DIN: 01764665

Encl. as above



Place: Hyderabad

Date: 28.04.2023

CERTIFICATE UNDER REGULATION 40 (9) OF THE SEBI (LODR) REGULATIONS, 2015 FOR THE YEAR ENDED 31.03.2023

I have examined all Share Transfer forms, Memorandum of Transfers, Registers, files and other documents relating to CONCORD DRUGS LIMITED, Hyderabad maintained by AARTHI CONSULTANTS PRIVATE LIMITED, Hyderabad pertaining to transfer of equity shares of the company for the period from 01.04.2022 to 31.03.2023 for the purpose of issuing a Certificate as per Regulation 40(9) of the SEBI (LO&DR) Regulations, 2015, by CONCORD DRUGS LIMITED and based on the information provided by the Company, I hereby certify that there was no case for lodgement for physical transfer, sub-division, consolidation, renewal, exchange of share certificate(s) or endorsement of calls/allotment monies for the period 01.04.2022 to 31.03.2023 and therefore no share certificate was issued.

For Vivek Surana & Associates

Vivek Surana Proprietor

M. No.: A24531, C.P. No.: 12901 UDIN: A024531E000219902

PR: 1809/2022